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ORIGINAL ARTICLES
Combination antiretroviral therapy (ART) has substantially
improved the prognosis of HIV-infected individuals, resulting
in a precipitous drop in AIDS-related mortality in affluent
countries.1-3 In contrast, in the most heavily burdened
developing countries of the world, the response to the
epidemic has focused on prevention. Prevention strategies have
not been successful and the combination of large numbers of
HIV-infected individuals compounded by unequal access to
medical resources, has resulted in an ever-widening life
expectancy gap between wealthy and developing countries.4 In
response to this crisis, the World Health Organisation (WHO)
has called for expanded access to ART in resource-poor
countries.5 ART programmes have been successfully
incorporated into highly divergent medical environments.
Brazil, a middle-income developing country, has incorporated
ART into its public health system 6 and a successful ART
programme has been implemented in rural Haiti, the poorest
country in the Western hemisphere.7
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Objectives. To report on operational and clinical problems
encountered during the first 6 months of a community-based
antiretroviral therapy (ART) programme.
Methods. ART was implemented in a primary care setting
utilising an easily replicable service-delivery model based on
a medical officer and nurse. Therapeutic counsellors,
themselves HIV-infected, provided counselling and adherence
support. Drug and monitoring costs were charitably funded
and provincial health authorities supplied the medical
infrastructure. The HIV Research Unit, University of Cape
Town, supplied training and additional clinical support. Local
HIV primary care clinics provided patient referrals.
Standardised ART regimens were used with strict entry
criteria (AIDS or CD4 count < 200 cells/µl). 
Results. Demand for the service was high. Referred patients
had advanced disease (AIDS 57%, median CD4 count 96/µl)
and high pre-treatment mortality (83/100 person-years).
Mycobacterial disease was a major contributor to this
mortality (40%). Scheduled clinic visit hours were six times
higher during recruitment than maintenance. Attributable
costs were: drugs 61%, staff 27%, viral load and CD4 cell
counts 10% and safety monitoring 2%. Viral load after 16
weeks of therapy was < 400 copies/ml in the first 16 patients.
Conclusions. ART can be successfully implemented within a
primary care setting. Drug purchases and staff salaries drive
programme costing. The service model is capable of
managing 250 - 300 patients on chronic ART, but staffing
needs to be increased during recruitment. Attention must be
given to the diagnosis of  tuberculosis during screening and
early ART. Incorporating therapeutic counsellors into the
programme increased community involvement and utilised a
valuable and previously untapped resource. 
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In South Africa, AIDS is now the major cause of death
among young adults.8 While ART is available to thousands of
South Africans in the private medical sector,9 there is little or no
ART access in the public sector, despite demands for such
therapy from the HIV-infected community.10 It has been argued
that ‘where HIV is the leading cause of death, a basic minimum
package that does not include antiretrovirals is not worthy of
the name’.7
In this paper we report on the initial medical, ethical and
logistic challenges of initiating a community-based ART pilot
project in a district where there is an existing network of HIV
primary health care (PHC) clinics. The project was called
Usapho Lwethu (My Family), since treatment was offered to
individuals and their partners and children wherever
appropriate. An easily replicable service delivery model was
chosen based on a team consisting of a medical officer, nurse
and therapeutic counsellors. In order to minimise operational
complexity, standardised ART regimens were used11,12 which
complied with international5 and national treatment
guidelines.13 To facilitate expansion of this or similar service
delivery models for ART elsewhere in South Africa, there is
urgent need to report and share knowledge of the operational
challenges that need to be overcome. 10
Methods
The ART clinic was situated in the Guguletu Community
Health Centre in the Nyanga district of Cape Town, which has
a population of 325 436 (projected figure from 1996 census
data). There are 10 primary care HIV clinics within the district,
which served as the patient referral base. Each clinic had
trained staff able to provide voluntary testing and counselling
services together with prophylaxis and outpatient management
of common HIV opportunistic infections. Patients requiring
inpatient care were referred to a local 200-bed secondary
hospital. 
Funding for antiretroviral medication, viral load
measurements and CD4 cell counts, sufficient for 150 patients,
was provided by UK-based charities. The local Community
Health Service Organisation and AIDS Directorate of the
Western Cape provided clinic space and medical support
services, together with dedicated clinic staff, consisting of a
medical officer and nurse. Training, clinical support, protocol
development and programme evaluation were provided by the
HIV Research Unit of the University of Cape Town. 
In August 2002, medical staff of the referring PHC clinics
were invited to workshops, where eligibility criteria and
patient referral mechanisms were discussed. Referring doctors
were requested to select suitable drug-naïve candidates from
their regular clinic attendees and to fax contact details and a
medical summary to the programme nurse. The medical
criteria for ART eligibility were either a prior AIDS diagnosis
or a CD4 cell count less than 200 cells/µl.5
Branded medications registered with the Medicines Control
Council of South Africa were used in standard doses. ART
consisted of two schedules, an initial non-nucleoside reverse
transcriptase (NNRTI)-based regimen of stavudine (d4T),
lamivudine  (3TC) and efavirenz (nevirapine was substituted
for efavirenz in women of child-bearing potential), with a
second protease inhibitor (PI)-based regimen of zidovudine
(AZT), didanosine (ddI) and Kaletra. Medication was sourced
from a single pharmaceutical supplier with a rapid delivery
turnaround time, to minimise on-site drug stocks. Drugs were
packaged for each named patient and supplied in 4 x 30 day
packs and stored in a secure locked section of the main clinic
pharmacy.
During September 2002, the first patients were recruited into
the programme, with a schedule of visits as follows: –4 weeks,
–2 weeks, treatment initiation, +4 weeks, +8 weeks, +16 weeks
and then at 16-week intervals. The early schedule of visits was
truncated for women in the latter stages of pregnancy, to
maximise therapeutic benefit to mother and baby. At the
screening visit (week –4), potential candidates were allocated a
therapeutic counsellor, whose responsibility was to provide
ongoing counselling support, to reinforce the need for high
levels of adherence, to maintain communication between
clients and the clinic staff and to visit clients in their homes.
The therapeutic counsellors were HIV-infected individuals,
many on ART themselves, who had been trained in drug
adherence and ART toxicity recognition by a non-governmental
organisation, Sizophila. The therapeutic counsellor/patient ratio
was 1:20. At this initial visit, a treatment readiness assessment
questionnaire was completed and 4 weeks of co-trimoxazole
were dispensed, with pill counts performed after 14 and 28
days to assess adherence. All patients had a checklist
completed, which screened for symptoms and signs of
tuberculosis (TB) infection. At the week –2 visit, blood was
taken for quantitative viral load and CD4 cell count. These tests
were repeated at 16-week intervals thereafter. Drug safety
monitoring of liver function test (LFT) and full blood count
(FBC) were also performed at weeks –2, +8 and 16-weekly
thereafter, with an additional LFT performed at week +2 in
those receiving nevirapine to screen for potential
hepatotoxicity. The final decision to commence or defer
initiation of ART was made at a combined meeting of medical
and therapeutic counsellors during the third week (week –1),
when information on clinical status, blood tests, treatment-
readiness and adherence data were available. Following this
meeting, drugs were ordered for those commencing ART. The
cohort pre-ART period was defined as the cumulative number
of days between the screening visit and the date of either
commencement of ART or permanent deferral. The ART
exposure period was defined as the cumulative number of
days from ART commencement to the censoring date of 
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28 February 2003. Resource utilisation data including
scheduled and non-scheduled visits and staff allocated time
were prospectively collected in a clinic register. Clinical,
laboratory and adherence data were kept in an electronic
database. 
Results
The number of eligible patients referred and their subsequent
status within the programme are outlined in Fig. 1. The mean
age of those screened was 34 years (range 7 - 55 years); 78%
were female. The population had advanced HIV infection, with
95% having symptomatic disease (WHO clinical stages 3 and 4)
and 57% having AIDS (WHO clinical stage 4). The median CD4
count was 96 cells/µl (range 3 - 452 cells/µl), and the median
viral load was 4.91 logs (range 2.611 ‡ 500.000). 
Eight patients were permanently deferred; 4 because of
failure or inability to attend clinic visits, 1 because of advanced
debilitating HIV disease and multidrug-resistant pulmonary
tuberculosis, 2 because of asymptomatic HIV and CD4 cell
counts above entry criteria at screening, and 1 because he
denied being HIV-infected. One patient was withdrawn after
therapy commenced because of failure to attend clinic visits.
Viral load data at 16 weeks were available for the first 16
patients, all of which were < 400 copies/ml. The first child
born to a mother on the programme was HIV PCR-negative at
3 months. 
Five deaths occurred between screening and the
commencement of ART or treatment deferral. The total pre-
ART period for the cohort was 2 186 days, which translated to
a pre-treatment crude mortality rate of 83/100 patient years.
Two of the five patients had active Mycobacterium tuberculosis
infection. Four deaths occurred on ART, none of which was
directly related to ART. The period of ART exposure up to the
censoring date totalled 4 271 days.
The proportional costs of drugs, staffing, quantitative viral
load with CD4 cell counts and laboratory safety monitoring are
shown in Fig. 2. Programme costs were dominated by drug
procurement and personnel costs. Of the personnel costs, the
medical officer contributed 39.3%, the nurse 16%, Sizophila
counsellors 15.7% and specialist medical support and training
29%.
Patient referrals reached 150 after 8 weeks of the programme.
Initiation of the 150 patients onto ART was scheduled over 9
months, with a mean of 15 patients starting therapy per month.
In the first 6 months there were 421 scheduled and 20
unscheduled visits. Duration of scheduled visits varied
between 15 minutes for a week-8 visit and 45 minutes for a
treatment-initiation visit. The number of scheduled clinic hours
per week was not evenly distributed and the projected weekly
scheduled visit hours required for the programme are shown in
Fig. 3. 
Discussion
This ART pilot project is a unique collaboration between
funding organisations from a developed country, local and
Fig. 1. Numbers of patients referred, screened and started on the
antiretroviral therapy (ART) programme, together with their status
within the programme and clinical and virological outcomes at week
16. Events occurring on ART are shown in the shaded boxes.
Referred
N = 183
Awaiting screen
N = 94
Awaiting ART
N = 12
Viral load < 400
N = 16
Viral load > 400
N = 0
Awaiting viral load
N = 41
Screened
N = 89
Started ART
N = 62
Deferred
N = 8
Died pre-ART
N = 5
Died on ART
N = 4
Withdrawn
N = 1
   
  
 
  
    
 
 
 
 
Fig. 2. The first 6 months’financial costs of the programme
introducing ART to an HIV primary care service. The attributable
proportion of costs for the following components are shown: drug
acquisition; staffing — medical, nursing and counsellors; monitoring
of CD4 and viral load; and laboratory safety monitoring.
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regional public sector health authorities and a local academic
institution. The programme was designed to identify the
attributable resources needed when adding an ART
programme to an existing primary care HIV service using an
easily reproducible service model. 
Public debate around treatment access, together with the
large numbers of HIV-infected individuals with advanced
disease, has created a backlog of demand for access to ART.
The programme was initially limited by funding sources to
treatment of 150 individuals. Recruitment to the programme
was completed by 8 weeks, confirming a high demand for ART
in our patient population. Many patients are desperate to
access therapy and perceive that they may not survive a delay
of several weeks. The clinic nurse highlighted this therapeutic
urgency when she reported her distress at ‘watching patients’
faces, informed of the waiting time before they access
antiretroviral therapy’. 
Initiation of ART was staggered over 9 months, which still
resulted in staffing time requirements peaking at
approximately six times the level required for subsequent long-
term management of these patients. The high clinic time
requirement resulted from the combined effects of the
recruitment rate, increased frequency of protocol-required
visits and increased time per visits during the early weeks of
ART initiation. The team of medical officer, nurse and
therapeutic counsellors allocated to the clinic would be
sufficient to supply 20 hours per week of scheduled clinic
visits, enough for a daily clinic of 4 hours’ duration. This
scheduled clinic time could service 250 - 300 patients on stable
ART; however, it is insufficient for the recruitment and
initiation phase of the ART programme. In any new
programme this increased staffing requirement will coincide
with the need for staff training in ART. Our training personnel
were able to provide the extra staffing capacity during the
recruitment phase. There will be a need for programmes to
allocate increased logistical support to ART clinics during the
initial ‘set-up’ phase.    
Patients on the programme had a functional status sufficient
to be able to attend an outpatient clinic; however, the pre-
treatment crude mortality rate was 83/100 patient years. The
on-treatment mortality showed significant decline; the
mortality rate has not been presented at this stage because the
drug exposure period is subject to a major confounder of ‘right
censoring’ and these data will be reported later. TB was a
significant contributor to mortality and the exclusion of active
TB presents a particular challenge to those initiating ART in
high TB-prevalence populations such as South Africa.14,15
Present treatment guidelines5,13 give an upper threshold of
200 CD4 cells/µl for initiating therapy, but there is no lower
limit. This introduces the dilemma of whether patients are ever
too sick to join a programme. While the sickest patients have
much to gain, they utilise programme resources
disproportionately and a high death rate can impact negatively
on community perceptions of the programme and affect staff
morale adversely. The non-medical therapeutic counsellors
required specific counselling support around this issue. In an
analysis of 12 574 individuals on ART, the CD4 count and
clinical stage at the time of initiation of treatment were the
dominant prognostic factors.16 In a cohort with very advanced
HIV disease and low CD4 counts such as ours, between 11%
and 15% would be predicted to develop further AIDS-related
complications during the first year of therapy, with the
majority of these events occurring within the first 6 months.16
Despite this high predicted complication rate, European and
North American experience indicates that only 1.5 - 3.1% of
advanced patients with 50 - 100 CD4 cells/µl die in the first
year of ART.16 These data support initiation of therapy at low
CD4 counts, which can still result in a reasonable prognosis if
the initial complications around the time of starting therapy
can be managed. Staff of the clinic and referral hospital
therefore need a high level of expertise in the recognition and
management of medical complications occurring during early
ART, particularly if very ill patients are to be entered into a
programme.   
Drug procurement accounted for 61% of the attributable cost
of adding ART to the existing primary care HIV management
programme. Although retail costs of ART have declined in
South Africa in recent years, they remain a major obstacle to
wider implementation in the public sector. In the next few
months the programme is expected to access UNAIDS
preferential pricing which will reduce the cost of the initial
regimen to approximately 50% of current retail pricing.
Availability of generic formulations could reduce the cost of
our initial schedule by an additional 50%, to approximately
R350 per month.12,17 Medical specialist support contributed 29%
of initial staffing costs; however, this component will also
decrease as training requirements decline and an increasing
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Fig. 3. Number of hours of scheduled visits per week required for 150
patients initiating HAART over a 9-month period. There is an initial
staffing requirement, which peaks at approximately six times the
long-term staffing needs. 
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proportion of patients are stabilised on ART. Viral load and
CD4 cell measurement contributed 10% of total attributable
expenditure. Until recently these high-technology assays were
considered to be too expensive for ‘low-cost programmes’ and
the use of low-technology substitutes such as total lymphocyte
counts was proposed.5 The recent marked cost reduction of
these assays in South Africa makes low-technology substitution
less attractive.
The preliminary viral response data are very encouraging
and demonstrate that an ART programme can be initiated
successfully within an existing primary care facility. The ART
delivery model chosen was well suited for those districts with
an existing HIV primary care infrastructure. Expansion to other
sites will be dependent not only on funding for antiretrovirals,
but also on the allocation of sufficient resources for the
development of a training and support infrastructure,
particularly during the early recruitment phase of the
programme. There are significant ethical issues concerning the
selection of patients into an ART programme where resources
are very limited. While there is a need for clear, transparent
and strictly maintained criteria for ART access, 10 both the
inclusion and exclusion of very sick patients was very
challenging and stressful for the clinic team. Therapeutic
counsellors gave valuable input to the programme from
persons in the local community living with HIV and AIDS. The
incorporation of HIV-infected individuals as ‘treatment
buddies’ and to give counselling support meant that a
previously untapped resource of expertise and talent was
utilised. 
This programme was sponsored by CRUSAID and the
Hannan Trust, UK. 
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